A new biotech has risen from the ashes of Novartis’ red-hot $12 billion acquisition of muscular dystrophy specialist Avidity Biosciences. A spinout planned since that deal’s October announcement has now officially debuted as Atrium Therapeutics, with two preclinical cardio candidates in tow.
- Home |
- Atrium arises from Novartis’ Avidity buy with $270M, pair of preclinical cardio candidates
Atrium arises from Novartis’ Avidity buy with $270M, pair of preclinical cardio candidates
- February 27, 2026
Recent Posts
- Oil jumps 5% as Hormuz tanker attacks escalate, US Gulf hurricane shuts in production
- Crescent Energy to acquire Eagle Ford assets from Devon for $4.2 billion
- LNG market tightens into winter as Europe pulls US cargoes, China reopens contract talks
- EIA: US crude oil inventories down 3.2 million bbl
- Chevron restructures Bakken midstream agreements, transfers Hess Midstream stake
